Alvard Antonyan

Alvard Antonyan

Auto-generated profile, based on publicly available information

Alvard Antonyan

Buniatian Institute of Biochemistry, National Academy of Sciences of the Republic of Armenia, Yerevan, Republic of Armenia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Neurochemistry International
Verified
Journal Article
Closed access
AAAlvard Antonyan
Alvard Antonyan
DSDagmar Schlenzig
Dagmar Schlenzig
SSStephan Schilling
Stephan Schilling
MNMarcel Naumann
Marcel Naumann
AAArmen Andreasyan
Armen Andreasyan
HDHans-Ulrich Demuth
Hans-Ulrich Demuth

1 April 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
KZKarina Zeyer
Karina Zeyer
OBOlivier Bornert
Olivier Bornert
VNValentin Nelea
Valentin Nelea
XBXinyi Bao
Xinyi Bao
ALAlexandre Leytens
Alexandre Leytens
ANAlexander Nyström
Alexander Nyström
Fibronectin serves as a platform to guide and facilitate deposition of collagen and fibrillin microfibrils. During development of fibrotic diseases, altered fibronectin deposition in the extracellular matrix (ECM) is generally an early event. Following this, dysregulated organization of fibrillins and fibrillar collagens occurs. Because fibronectin is an essential orchestrator of healthy ECM, perturbation of its ECM-organizational capacity may be involved in development of fibrosis. To investigate this, we employed recessive dystrophic epidermolysis bullosa (RDEB) as a disease model with progressive, severe dermal fibrosis. Fibroblasts from RDEB donors in 2D and 3D cultures displayed dysregulated fibronectin deposition. Our analyses revealed that increase of pro-fibrotic DPP4+ fibroblasts coincides with altered fibronectin deposition. DPP4 inhibitors normalized deposition of fibronectin and subsequently of fibrillin microfibrils and collagen I. Intriguingly, proteomics, inhibitor and mutagenesis studies disclosed that DPP4 modulates ECM deposition through proteolysis of the fibronectin N-terminus. Our study provides mechanistic insights to the observed pro-fibrotic activities of DPP4 and extends the understanding of fibronectin-guided ECM assembly in health and disease.

29 January 2024 in Reviews in the Neurosciences
Verified
Journal Article
Closed access
SMSona Mardanyan
Sona Mardanyan
AAArmen Andreasyan
Armen Andreasyan
AAAlvard Antonyan
Alvard Antonyan
Fibril formation by amyloidogenic proteins and peptides is considered the cause of a number of incurable diseases. One of the most known amyloid diseases is Alzheimer’s disease (AD). Traditionally, amyloidogenic beta peptides Aβ40 and Aβ42 (Aβs) are considered as main causes of AD and the foremost targets in AD fight. The main efforts in pharmacology are aimed at reducing Aβs concentration to prevent their accumulation, aggregation, formation of senile plaques, neuronal death, and neurodegeneration. However, a number of publications have demonstrated certain beneficial physiological effects of Aβs. Simultaneously, it is indicated that the effects of Aβs turn into pathological due to the development of certain diseases in the body. The accumulation of C- and N-terminal truncated Aβs under diverse conditions is supposed to play a role in AD development. The significance of transformation of glutamate residue at positions 3 or 11 of Aβs catalyzed by glutaminyl cyclase making them more degradation resistant, hydrophobic, and prone to aggregation, as well as the participation of dipeptidyl peptidase IV in these transformations are discussed. The experimental data presented confirm the maintenance of physiological, nonaggregated state of Aβs by plant preparations. In conclusion, this review suggests that in the fight against AD, instead of removing Aβs, preference should be given to the treatment of common diseases. Glutaminyl cyclase and dipeptidyl peptidase IV can be considered as targets in AD treatment. Flavonoids and plant preparations that possess antiamyloidogenic propensity are proposed as beneficial neuroprotective, anticancer, and antidiabetic food additives.

1 June 2026 in Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry
Verified
Journal Article
Closed access
PDF file
AAA. Antonyan
A. Antonyan
RBR. Balagyozyan
R. Balagyozyan
ABA. Bakaryan
A. Bakaryan
AAA. Avetisyan
A. Avetisyan
VMV. Mukuchyan
V. Mukuchyan
SMS. Mardanyan
S. Mardanyan
It was proved that adenosine deaminase (ADA) accumulates in synovial fluids (SFs) in rheumatoid arthritis (RA), reducing the anti-inflammatory adenosine concentration and exacerbating inflammation. Therefore, ADA inhibiting as an inflammation supporting agent may be beneficial in RA treatment. The quest for the new enzyme inhibitors is a relevant task. The aim of this work was to investigate the influence of the water and ethanol extracts of Origanum vulgare L. (OVL) from Armenian landscape on ADA activity. The influence of the extracts on ex vivo ADA activity in two groups of SFs from RA patients with differing the enzyme activity demonstrated more effective inhibition in SFs with higher ADA activity for both extracts. Two isoforms of ADA were purified to elucidate which one is the main factor responsible for the observed enzyme inhibition. There was no significant difference in inhibition of large isoform of ADA from human erythrocytes and RA SFs. The evaluated IC50 values for small isoform of ADA (SADA) evidenced 1.5 times more effective inhibition in vitro citrullinated enzyme compared to the non-citrullinated one. Considering the accumulation of citrullinated SADA in RA SFs enhances inflammation by metabolizing adenosine, the obtained results suggest OVL is a promising source of anti-inflammatory agent for the development of new therapeutic medicines for RA.